New Research on Neoantigens and Tumor-targeting T-cells Marks Paradigm Shift in Countering Solid Tumors
Cancer immunotherapies based on therapeutic vaccination or transfer of tumor-infiltrating lymphocytes (TILs) are heralded as one of the most important advancements in the management of solid tumors. The precise identification of clinically relevant tumor antigens and their cognate TCRs is a critical foundation for such therapies.
However, the biggest challenge is the low frequency of these neoantigen-specific T-cells in peripheral blood lymphocytes (PBLs) and tumor-infiltrating lymphocytes. Thus, designing effective antigen screening methodology, in vitro TIL expansion, optimizing antigen validation has gained much attention recently.
In a breakthrough study, scientists from the Ludwig Institute of Cancer Research led by investigator Alexandre Harari and George Coukos, Director of the Lausanne Branch of the Ludwig Institute for Cancer Research, developed a highly efficient method, ‘NeoScreen,’ an in vitro TIL expansion and screening methodology that aims at sensitive identification of rare tumor (neo) antigens and of cognate T cell receptors (TCRs) expressed by tumor-infiltrating lymphocytes.
However, the biggest challenge is the low frequency of these neoantigen-specific T-cells in peripheral blood lymphocytes (PBLs) and tumor-infiltrating lymphocytes. Thus, designing effective antigen screening methodology, in vitro TIL expansion, optimizing antigen validation has gained much attention recently.
In a breakthrough study, scientists from the Ludwig Institute of Cancer Research led by investigator Alexandre Harari and George Coukos, Director of the Lausanne Branch of the Ludwig Institute for Cancer Research, developed a highly efficient method, ‘NeoScreen,’ an in vitro TIL expansion and screening methodology that aims at sensitive identification of rare tumor (neo) antigens and of cognate T cell receptors (TCRs) expressed by tumor-infiltrating lymphocytes.
GO Prime with only $1.49 now
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23